Aim: Previous epidemiological studies demonstrated that the ratio of n-6 to n-3 polyunsaturated fatty acids is associated with cardiovascular diseases. We herein investigated whether the beneficial effect of highly purified eicosapentaenoic acid (EPA) on arterial stiffness is associated with changes in the ratio of polyunsaturated fatty acids, such as EPA, docosahexaenoic acid (DHA) and dihomo-γ-linolenic acid (DGLA), relative to arachidonic acid (AA), in obese Japanese patients with dyslipidemia. Methods: The EPA/AA, DHA/AA and DGLA/AA ratios were compared between obese patients with (n=94) and without (n= 31) dyslipidemia. Among the former group, 88 patients received either highly purified EPA treatment (1.8 g daily, n = 45) or treatment without EPA (control, n = 43). Results: At baseline, the ratios of DHA/AA and DGLA/AA were significantly (P＜0.05) higher in obese patients with dyslipidemia than in those without, while the EPA/AA ratio was similar between patients with and without dyslipidemia. EPA significantly reduced the hemoglobin A1c, total cholesterol, triglycerides, CRP, cardio-ankle vascular index (CAVI) (an index of arterial stiffness) and the DGLA/AA ratio relative to the control at three months after the treatment. On the other hand, EPA significantly increased the adiponectin level and EPA/AA ratio (P＜0.05). A multivariate regression analysis revealed that only age, an increase in the EPA/AA ratio and a decrease in the CRP level were significant determinants of a reduction of the CAVI by EPA. Conclusion: These findings suggest that EPA improves the arterial stiffness in association with an increase in the EPA/AA ratio and a decrease in inflammation in obese patients with dyslipidemia. Thromb, 2014; 21:248-260. 
Introduction
In epidemiological studies and clinical trials, fish oils rich in n-3 polyunsaturated fatty acids (PUFAs) ratios appear to be involved in the development of cardiovascular diseases, it remains unclear which ratio of fatty acids has a stronger association with atherogenesis and cardiovascular events in obese patients.
As a first step to clarify this issue, we analyzed the associations between the arterial stiffness and the ratios of serum fatty acids (EPA, DHA and dihomo-γlinolenic acid [DGLA] ), relative to AA. In human plasma, fatty acids are incorporated mainly into TG, phospholipids and cholesterol esters in lipoprotein particles 25) . Therefore, the absolute value of fatty acid fractions is influenced by these lipid levels. In this study, we adopted relative values: EPA/AA, DHA/AA and DGLA/AA ratios, as reported previously 26, 27) . We herein report that the EPA/AA ratio is most strongly correlated with the improvement of arterial stiffness in obese dyslipidemic patients.
Methods

Subjects
A total of 125 Japanese obese patients (64 men and 61 women, mean age: 52.8±12.7 years, mean body mass index [BMI]: 30.4±4.9 kg/m 2 , median hemoglobin A1c [HbA1c]: 6.7% [interquartile range: 6.1-7.8%]) were consecutively enrolled in the outpatient clinic at the National Hospital Organization Kyoto Medical Center during the period from March 2010 to June 2012. We recruited obese subjects with a BMI of ≥ 25 kg/m 2 , based on the guideline proposed by the Japan Society for the Study of Obesity. This study is a part of the Japan Obesity and Metabolic Syndrome Study (JOMS), which has undergone clinical trial registration in the University Hospital Medical Information Network (UMIN) system (UMIN-StudyID: UMIN 000000559) 28) . Patients with severe renal diseases, severe liver dysfunction and secondary obesity due to endocrine disorders were excluded from this study. None of the patients had received anti-obesity drugs. The study protocol was approved by the Ethics Committee for Human Research at Kyoto Medical Center. Written informed consent was obtained from all participants.
Study Protocol
All 125 obese patients who were enrolled were further classified into those with and without dyslipidemia using the following criteria: a triglyceride (TG) level ≥ 1.69 mmol/L and/or high-density lipoproteincholesterol (HDL-C) level ＜1.04 mmol/L for men and ＜1.29 mmol/L for women, which are some of the components of the criteria used to diagnose metabolic syndrome proposed by the US National Choles-EPA did not change the low-density lipoprotein-cholesterol (LDL-C) levels 6) . We recently demonstrated that treatment with highly purified EPA decreased the small-dense LDL, oxidized LDL, high-sensitivity C-reactive protein (CRP) and the cardio-ankle vascular index (CAVI), a new index of arterial stiffness not influenced by the blood pressure, and increased the adiponectin level in obese Japanese patients. All of these effects of EPA may contribute to cardioprotection in patients with obesity and metabolic syndrome 7-10) .
It has been reported that n-3 PUFAs, including EPA and docosahexaenoic acid (DHA), exert antiplatelet and anti-inflammatory actions, in part through antagonizing the activity of proinflammatory eicosanoids derived from arachidonic acid (AA), one of the n-6 PUFAs 5, 11) . Previous epidemiological studies reported that high n-3/n-6 PUFA levels and the EPA/ AA ratio are associated with a low rate of ischemic heart disease 12, 13) . In addition, a sub-analysis of the JELIS and other studies suggested that a high serum EPA/AA ratio is significantly associated with a low incidence of cardiac death or myocardial infarction, and a low coronary plaque score 14, 15) . We also showed that the serum EPA/AA ratio in obese patients is associated with monocyte expression of IL-10, an antiinflammatory M2 marker 16) .
DHA and EPA are n-3 PUFAs, and may contribute to the prevention of atherosclerosis and inflammatory diseases 11, 17) . The Framingham Heart Study reported that a high plasma phosphatidylcholine DHA level was associated with a significant reduction in the risk of developing all-cause dementia 18) . On the other hand, several basic and clinical studies revealed differential effects of EPA and DHA on cardiovascular risk factors [19] [20] [21] . A cross-sectional observational study (ERA JUMP study) reported that the DHA, but not the EPA, level was negatively correlated with the carotid intima-media thickness (IMT), one of the representative atherogenic indicators 20) . In contrast, other studies reported that the EPA, but not DHA, level was negatively correlated with the carotid and femoral intima-media thickness 21, 22) . Moreover, a recent study showed that carotid atherosclerotic plaques in patients treated with n-3 polyunsaturated fatty acid ethyl esters (EPA and DHA) more readily incorporated EPA than DHA, and that the EPA content of plaque phospholipids was inversely associated with plaque instability and inflammation 23) . Therefore, the effects of EPA and DHA on atherosclerosis are not fully understood, and need to be further elucidated. In the sub-analysis of the JELIS, a high level of EPA, but not DHA, was inversely correlated with the risk of major coronary events 24) . While both low EPA/AA and DHA/AA DGLA and AA among the total fatty acids. In serum, most fatty acids are esterified in cholesterol and TG (or phospholipids), and these lipids are incorporated in lipoproteins such as VLDL and LDL, while a small part of the fatty acids are in a non-esterified (free) form and are bound to albumin. The composition of serum fatty acids was determined by capillary gas chromatography 14, 15) . The esterified and non-esterified (free) fatty acids of the serum total lipids were transesterified with methanolic hydrochloric acid. The methylated fatty acids were extracted with hexane and analyzed using a Shimadzu GC-2010 gas chromatograph (Shimadzu Corporation, Kyoto, Japan) with a BPX90 capillary column (0.25 mm internal diame-ter×100 m, SGE Analytical Science Pty., Ltd., Ringwood, Victoria, Australia).
Measurement of the CAVI
A Vasera VS 1000 (Fukuda Denshi, Tokyo, Japan) was used to obtain ECG, phonocardiographs, blood pressures and waveforms of the brachial and ankle arteries, as well as the pulse wave velocity (PWV) 10, 28) . CAVI values were automatically calculated by substituting the stiffness parameter β in the following equation to detect the vascular elasticity and the cardio-ankle PWV:
Stiffness parameter β= 2ρ×1/(Ps−Pd)×ln(Ps/Pd)
where ρ is the blood density, Ps and Pd are the SBP and DBP in mmHg, respectively, and the PWV is measured between the aortic valve and ankle. The CAVI, which represents the stiffness of the aorta, is therefore unaffected by the BP. The principles underlying the calculation of the CAVI have been described in detail by Shirai et al. 31) . The average coefficient of variation of the CAVI is less than 5%, which is small enough for clinical use and confirms that the CAVI has favorable reproducibility 31) .
Statistical Analysis
The data are presented as the means±SD or medians and interquartile ranges, and a value of P＜ 0.05 was considered to be significant. Student's t-test was used for comparisons of the means between two groups at the baseline or post-treatment. Categorical variables were evaluated by the χ 2 test. A repeatedmeasures ANOVA (control and EPA group×pre-and post-treatment) was used to assess the effects of EPA treatment on the measured variables. Then, for a significant variable identified by ANOVA, a two-tailed, paired t-test was applied to evaluate the changes in conditions from before to three months after treatment. Some of the data were not normally distributed;
terol Education Program-Adult Treatment Panel Ⅲ
(NCEP-ATP Ⅲ) 29) , as described previously 16) .
Of the 94 obese patients with dyslipidemia, six patients were excluded for the following reasons: five patients stopped consulting our clinic and one patient withdrew consent for their participation in the study. Accordingly, 88 patients in whom we could continue observations were assigned to the control and EPAtreated groups. This study was a prospective, randomized, open-label, blinded endpoint (PROBE) design, employing simple randomization. In the EPA-treated group, an EPA capsule (1.8 g daily) containing highly purified (＞98%) EPA ethyl ester (Mochida Pharmaceutical Co., Ltd., Tokyo, Japan) was administered for three months in addition to diet therapy, as previously described 7-10) . The three-month diet therapy was administered to both groups. The patients' diet was based on the Japan Atherosclerosis Society Guidelines for the Diagnosis and Treatment of Atherosclerotic Cardiovascular Diseases, as previously described 7-10) , consisting of 25 kcal/kg of the ideal body weight per day (60% of the total energy as carbohydrates, 15-20% as protein, 20-25% as fat). No patients in the control or EPA-treated groups underwent any changes in medication during this study. Several patients in both groups were taking oral antidiabetic agents (sulfonylureas, α-glucosidase inhibitors or metformins), antihypertensive agents (calcium channel blockers or angiotensin Ⅱ receptor antagonists) and/or lipid-lowering agents (statins or fibrates), all of which were used in the same proportion of patients in both groups. No patients in this study had taken part in any of our previous studies.
Data Collection and Laboratory Methods
At the beginning and end of the study, we measured the BMI, waist circumference, systolic and diastolic blood pressures (SBP and DBP, respectively), fasting plasma glucose (FPG), HbA1c, serum immunoreactive insulin (IRI), total cholesterol, TG, HDL-C and LDL-C, leptin, adiponectin and CRP, as described previously 7-10) . The value for HbA1c (%) was estimated as a National Glycohemoglobin Standardization Program (NGSP) equivalent value (%) calculated using the formula: HbA1c (NGSP)(%)=1.02×HbA1c (Japan Diabetes Society: JDS)(%)＋0.25% 30) . Serum was prepared by collecting blood into glass tubes without an anticoagulant, and was obtained by centrifugation (1,500×g, 10 min, 4 ℃), and aliquots of the supernatant were frozen (−80 ℃) until use.
Fatty Acid Analysis
We measured the serum levels of EPA, DHA, Windows (SPSS Inc., Chicago, IL, USA).
Results
Baseline Characteristics of Obese Patients with or without Dyslipidemia
A summary of the characteristics of the study cohort and a comparison of the obese patients with or without dyslipidemia are shown in Table 1 . Of all 125 obese patients (64 men and 61 women; mean age, 52.8 years), there were 94 (75.2%) with dyslipidemia. There were no significant differences in the age, SBP, DBP, FPG, IRI or CRP between those with and without dyslipidemia. The HbA1c, TC, TG, LDL-C and CAVI were significantly higher, and the BMI, waist circumference, HDL-C, leptin and adiponectin were significantly lower in obese patients with dyslipidemia than in those without. The AA, DHA and DGLA levels were significantly higher in obese patients with therefore, in these cases, the nonparametric Wilcoxon test was used instead of the t-test. Pearson's correlation coefficients were employed to investigate the correlations of the changes in the parameters (EPA, AA, DHA, DGLA, EPA/AA ratio, DHA/AA ratio, DGLA/ AA ratio, and CAVI) with the changes in metabolic parameters between measurements taken pre-and post-EPA treatment. The changes from the baseline to three months after treatment were abbreviated as Δ. A stepwise multivariate regression analysis clarified those factors related to the changes in the CAVI value between the pre-and post-EPA treatment after adjusting for the baseline CAVI, which affects the changes in the CAVI. The independent variables included in the multivariate regression analysis were the age, gender, smoking, changes in the ratios of fatty acids, and all metabolic variables that significantly changed after EPA treatment. All of the statistical analyses were performed using the SPSS 17.0 software program for in those without dyslipidemia, although the EPA level was not significantly different between the groups. The DHA/AA ratio was significantly higher in these obese patients with dyslipidemia than in those without, although the EPA/AA and DGLA/AA ratios were also not significantly different between the groups.
Effects of EPA Treatment on the Metabolic Variables and Composition of Serum Fatty Acids
The 88 obese patients with dyslipidemia in whom we could continue observations were randomly assigned to two groups: an EPA-treated group (n= 45, 24 men and 21 women; mean BMI, 29.6±4.4 kg/m 2 ) and an untreated control group (n = 43, 24 men and 19 women; mean BMI, 29.1±4.2 kg/m 2 ). No significant differences were observed in any variables between the control and EPA groups at baseline ( Table 2 ). The dyslipidemia than in those without, although the EPA level was not significantly different between the groups. The DHA/AA and DGLA/AA ratios were significantly higher in obese patients with dyslipidemia than in those without, although the EPA/AA ratio was not significantly different between the groups.
Of all 125 obese patients, 82 were not taking other lipid-lowering agents (statins or fibrates). A summary of the characteristics of these patients who were not taking statins or fibrates is shown in Supplemental Table 1 . The TC, TG, LDL-C and CAVI were significantly higher, and the BMI, waist circumference and adiponectin level were significantly lower in this sub-group of obese patients with dyslipidemia than in those without. Similar to the overall cohort of patients, the AA, DHA and DGLA level were significantly higher in these obese patients with dyslipidemia than AA ratio significantly increased, whereas the DHA/AA ratio remained unchanged and the DGLA/AA ratio significantly decreased after EPA treatment.
After three months of treatment, the EPA level and the EPA/AA ratio were significantly higher in the EPA group than in control group, whereas the other parameters did not show significant differences. Table 3 lists the data for all subjects regarding the simple correlations observed among the EPA, AA, DHA, DGLA, EPA/AA, DHA/AA and DGLA/AA ratios and the CAVI with the metabolic variables during the treatment. In all study subjects, Pearson's correlation coefficient revealed that the change in EPA was positively correlated with the EPA/AA ratio and the DHA/AA ratio, and negatively correlated with the changes in the TG, DGLA and DGLA/AA. The change in AA was positively correlated with the changes in the TC, TG, LDL-C, leptin, DHA and DGLA, and negatively correlated with the change in proportions of patients with prescriptions for antihypertensive, antidiabetic and lipid-lowering agents were not significantly different between the groups. In the control group, 17 and three patients took statins and fibrates, respectively, and in the EPA-treated group, 12 and five patients were taking these agents, respectively.
Correlations among the Changes in Metabolic Variables, the CAVI and the Composition of Serum Fatty Acids during EPA Treatment
With regard to the control group, the BMI, waist circumference, SBP, DBP, FPG, HbA1c, IRI, TC, TG, HDL-C, LDL-C, leptin, adiponectin, CRP, CAVI, EPA, AA, DGLA, the EPA/AA ratio and the DGLA/ AA ratio remained unchanged throughout the study, although the DHA level and the DHA/AA ratio were increased. In the treatment group, after three months of treatment with EPA, an analysis of variance showed that the HbA1c, TC and TG significantly decreased, whereas the BMI, waist circumference, SBP, DBP, FPG, IRI, HDL-C, LDL-C and leptin level remained unchanged. EPA treatment significantly increased the serum adiponectin level and decreased the CRP level and the CAVI, which was consistent with our previous reports 7-10) . The serum EPA level significantly increased, and the AA, DHA and DGLA levels significantly decreased after EPA treatment. The serum EPA/ EPA level and the EPA/AA ratio ( Table 3 and Fig.  1A) . Neither the change in the DHA/AA ratio nor that in the DGLA/AA ratio was significantly correlated with a decreased CAVI following EPA treatment ( Table 3 and Fig. 1B, C) . For the other metabolic parameters, the changes in the CAVI were significantly positively correlated with the changes in the TG and CRP levels ( Table 3) .
The stepwise multivariate regression analysis revealed that the age, an increase in the EPA/AA ratio and a decrease in the CRP level were independent determinants of a decreased CAVI during treatment with EPA after adjusting for the baseline CAVI, which affects the changes in the CAVI (R 2 = 0.236, Table 4 ).
Discussion
The present study investigated the ratios of fatty acids and the arterial stiffness in obese Japanese patients. Several reports have shown the effects of EPA treatment on atherogenic indicators or cardiovascular the EPA/AA ratio. The change in DHA was positively correlated with the changes in the TC, TG, AA, DGLA and DHA/AA, and negatively correlated with the change in adiponectin. The change in DGLA was positively correlated with the changes in the TC, TG, leptin, AA, DHA and DGLA/AA, and negatively correlated with the change in the EPA level and the EPA/ AA ratio.
The change in the EPA/AA ratio was positively correlated with the changes in EPA, and negatively correlated with the changes of the IRI, TG, AA, DGLA and DGLA/AA. The change in the DHA/AA ratio was positively correlated with the changes in the EPA and DHA levels, and negatively correlated only with the change in the adiponectin level. The change in the DGLA/AA ratio was positively correlated with the changes in the BMI, TG, leptin, CRP and DGLA, and negatively correlated with the change in the EPA level and the EPA/AA ratio. Furthermore, the change in the CAVI during treatment with EPA was significantly negatively correlated with the change in the A. The association of the change in the CAVI with that in the EPA/AA ratio after three months of treatment. B. The association of the change in the CAVI with that in the DHA/AA ratio after three months of treatment. C. The association of the change in the CAVI with that in the DGLA/AA ratio after three months of treatment. Pearson's correlation coefficients (r) and associated P values (p) are shown for the whole subjects (n = 88). The abbreviations used in this figure are the same as those in Table 1 .
A C B els of DGLA in plasma phospholipids were higher in children with metabolic syndrome than in those without 37) . However, as there have been few studies that have reported the serum DGLA levels in adult obese patients with dyslipidemia, further studies on the mechanisms underlying the high AA, DHA and DGLA levels in obese dyslipidemic patients are needed.
The present study demonstrated that threemonth EPA treatment significantly reduced the CAVI, consistent with our previous report 10) . Our results were also compatible with previous reports showing the beneficial effects of EPA on atherogenic indices, such as the carotid artery IMT, brachial-ankle PWV (baPWV) and arterial stiffness assessed by the strain rate using tissue Doppler imaging [38] [39] [40] . The CAVI is correlated with the carotid IMT, an independent predictor of cardiovascular events, and is associated with the cardiac function and coronary atherosclerosis 41, 42) . We previously reported that the CAVI was correlated with the severity of metabolic syndrome and hypoadiponectinemia, relative to the baPWV, suggesting the usefulness of CAVI measurement in subjects with metabolic syndrome 28) .
Among the various lipid profiles, the changes in the TG, EPA and the EPA/AA ratio were associated with a reduction of the CAVI, whereas changes in other serum lipids (TC, HDL-C and LDL-C) and other fatty acid ratios (DHA/AA and DGLA/AA) were not. In addition, a multivariate regression analysis revealed that only an increase in the EPA/AA ratio was associated with a reduction of the CAVI, whereas changes in other serum lipids (TC, TG, and LDL-C) and other fatty acid ratios (DHA/AA and DGLA/AA) were not. Our findings are consistent with those of a previous study by Yamakawa et al., showing that the endothelium-dependent function during EPA treatment was specifically associated with the ratio of EPA/ AA, but not with the levels of other serum lipids (TC and LDL-C) or other fatty acid ratios 32) . Taken events 6, 10, 32) , and cross-sectional studies have described the relationships between the EPA/AA ratio and atherogenic indicators 14, 33, 34) . However, there has been no report on the tripartite associations among EPA treatment, the EPA/AA ratio and atherogenic indicators. This is the first study to demonstrate that EPA has an anti-atherogenic effect, as measured by the CAVI, in association with an increase in the EPA/AA ratio, independent of the effects of other lipids.
At the baseline, the serum AA, DHA and DGLA levels in patients with dyslipidemia were significantly higher than in those without dyslipidemia. In the serum, most fatty acids are esterified in cholesterol and TG (or phospholipids), and these lipids are incorporated in lipoproteins such as VLDL and LDL, while a small part of the fatty acids are in a non-esterified (free) form that is bound to albumin. Accordingly, in obese patients with dyslipidemia, the absolute values of fatty acids such as AA, DHA and DGLA, tend to increase concomitantly with the increase in TC and TG. In order to normalize these effects, we utilized the ratio of fatty acids, such as the DHA/AA ratio, to evaluate the composition of each fatty acid in the patients. In this study, the ratios of DHA/AA and DGLA/AA were significantly increased in obese patients with dyslipidemia. In the JELIS participants, the changes in DHA were positively correlated with those in LDL-cholesterol after EPA treatment 35) . Recently, Ishida et al. reported that, in hamsters fed a high-fat diet, DHA significantly increased the LDL-C levels, whereas EPA had no effect on the LDL-C levels. DHA, but not EPA, increased the plasma cholesterylester transfer protein (CETP) activity and decreased the LDL receptor expression in the liver 36) . These mechanisms may, at least partly, underlie the higher DHA/AA ratios found in obese patients with dyslipidemia compared to those without dyslipidemia in our study. Regarding the DGLA/AA ratio, our data are consistent with a previous report showing that the lev- were no significant correlations between the TG and the baPWV, FMD or CAVI 10, [52] [53] [54] . These differences might be due to the varying conditions in the studies, such as the subjects and methods. The multivariate regression analysis in the present study demonstrated that the ΔEPA/AA ratio, but not the ΔTG, was a significant independent contributor to the ΔCAVI. These findings suggest that the ΔEPA/AA ratio, rather than the ΔTG, is a stronger independent factor influencing the ΔCAVI. However, further studies are needed to clarify the relationships among the TG, EPA treatment and atherogenic indicators. It has been recognized that EPA is metabolized to DHA, and EPA and its metabolites are integrated into lipoproteins in the plasma and most of the tissue phospholipids 25) . DGLA, an n-6 PUFA, provides antiinflammatory benefits. The present study demonstrated that three-month treatment with EPA did not change the DHA/AA ratio, but decreased the DGLA/ AA ratio. While the mechanisms underlying EPA's effects on the DGLA/AA ratio are unclear, these results are compatible with a recent report showing that treatment with EPA decreased the serum DGLA level, but did not alter the serum DHA level 32) .
Both EPA and DHA have been reported to be generally beneficial in inflammatory and cardiovascular disorders. However, several studies have shown that EPA and DHA exert differential effects on several functions of leukocytes, insulin-secreting cells and endothelial cells 19) . In this study, the increase in the EPA/AA ratio, but not the DHA/AA ratio, was associated with the reduction of the CAVI by EPA treatment. Recent clinical studies, including a sub-analysis of the JELIS, suggested that a decreased serum EPA/ AA ratio is significantly associated with the incidence of cardiac death or myocardial infarction 14, 33, 55) . Therefore, the results of our study are compatible with those of these clinical studies. Mishina et al. showed that, in patients with ischemic stroke, the modified Rankin Scale, one of the assessment tests for clinical severity, was negatively correlated with the EPA/AA ratio and positively correlated with the DHA/AA ratio 27) . In addition, the Hisayama Study suggested that a lower EPA/AA level is associated with a greater risk of death from cardiovascular causes in the general Japanese population 56) . On the other hand, a population-based cross-sectional study reported that DHA, but not EPA, has an inverse association with the carotid IMT 20) . Thus, a long-term prospective cohort study with a larger sample size is required to clarify the causal relationship between the changes in the ratios of fatty acids and cardiovascular events. together, our results and those of other studies suggest that EPA improves the arterial stiffness and vascular function mainly through the increase in the EPA/AA ratio.
EPA can not only replace AA in phospholipid bilayers, but is also a competitive inhibitor of cyclooxygenase, reducing the production of 2-series prostaglandins and thromboxane 43) . The mechanism by which EPA and DHA confer cardiovascular protection may involve a replacement of AA in vascular and cardiac membrane phospholipids 35) . The OCEAN Study showed that carotid atherosclerotic plaques in patients treated with n-3 PUFA ethyl esters (EPA and DHA) readily incorporate EPA, but not DHA, and that the EPA content of plaque phospholipids was inversely correlated with plaque instability and inflammation 23) . Accordingly, these findings suggest that EPA is incorporated into both serum lipoproteins and arteries, and antagonizes the atherogenic effects of AA both locally and systemically.
The multivariate regression analysis in this study revealed that the significant determinants of a decrease in the CAVI during EPA treatment were the patient age, the increase in the EPA/AA ratio and the decrease in the CRP. We previously reported that EPA significantly decreases the serum CRP level, a representative marker of inflammation, in patients with metabolic syndrome 7) . EPA exerts an anti-inflammatory effect, in part, by antagonizing the production and function of pro-inflammatory eicosanoids derived from AA 5, 11, 23) . In addition, a single correlation analysis revealed that the ΔEPA/AA, but not ΔDHA/AA, was negatively correlated with the ΔIRI and ΔTG. Therefore, the increase in the EPA/AA ratio may contribute to the amelioration of insulin resistance and hypertriglyceridemia, which might provide a mechanism for the improvement of arterial stiffness in obese patients.
There was a significant correlation between the ΔTG and the ΔCAVI in the present study, consistent with our previous report 28) . The Japan Diabetes Complications Study also revealed that, in type 2 diabetic patients, the serum TG, as well as LDL-C, levels were leading predictors of coronary heart disease 44) . For more than two decades, studies have reported a positive relationship between the TG level and atherosclerotic indicators, such as the baPWV [45] [46] [47] , IMT 48) , forearm blood flow measured with plethysmography 49) , wall thickness measured with echocardiography 50) and flow-mediated dilation (FMD) 51) . In addition, an observational study reported that a decrease in the TG level due to pharmacological therapy was associated with improvement of the baPWV 45) and FMD 51) . In contrast, other studies reported that there tion with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet, 1999 
Conclusion
This study showed that EPA treatment significantly increased the serum EPA/AA ratio, decreased the DGLA/AA ratio and did not change the DHA/AA ratio in obese patients with dyslipidemia. In addition, only the increase in the EPA/AA ratio, the patient age and the decrease in the CRP level were associated with the reduction of the CAVI, whereas changes in other serum lipids (TC, HDL-C and LDL-C) and other fatty acids (DHA/AA and DGLA/AA) were not. So far, there has been no report on the tripartite associations among EPA treatment, the change in the EPA/ AA ratio and the changes in atherogenic indicators. Therefore, this is the first study demonstrating that EPA improves the arterial stiffness in association with an increase in the EPA/AA ratio in obese dyslipidemic patients, independent of other lipids. The change in the serum EPA/AA ratio may be the most useful biomarker for predicting the beneficial effects of EPA treatment on atherogenic risks in obese patients with dyslipidemia. 
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Abbreviations: BMI, body mass index; HbA1c, hemoglobin A1c; IRI, immunoreactive insulin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; CRP, high-sensitive C-reactive protein; CAVI, cardio-ankle vascular index; EPA, eicosapentaenoic acid; AA, arachidonic acid; DHA, docosahexaenoic acid; DGLA, dihomo-gamma-linolenic acid. The data are expressed as the means±SD or median (interquartile range). ＊ P＜0.05 vs. non-dyslipidemia measurements as determined by the t-test, nonparametric Wilcoxon test (for variables expressed as medians) or χ 2 test.
